A group of scientists, including Sergey Frolov, professor of physics at the University of Pittsburgh, and co-authors from ...

An AI model that learns without human input—by posing interesting queries for itself—might point the way to superintelligence ...

Tessellations aren’t just eye-catching patterns—they can be used to crack complex mathematical problems. By repeatedly reflecting shapes to tile a surface, researchers uncovered a method that links ...

In a sense, it sounds like that’s another facet of computational thinking that’s more relevant in the age of AI—the abstractions of statistics and probability in addition to algorithms and data ...

Neuromorphic computers, inspired by the architecture of the human brain, are proving surprisingly adept at solving complex ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...